When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Halozyme Therapeutics (NASDAQ:HALO) has launched its oral testosterone therapy Tlando. The drug was approved by the U.S. FDA on March 28. Tlando marks Halozyme's second hormone replacement therapy. Xyosted, which is given weekly via subcutaneous auto-injector, was approved in 2018. See why Seeking Alpha contributor Biologics says that Halozyme's (HALO) deal to acquire Antares Pharma improves the company's growth prospects.